Pronađeno: 1-2 / 2 radova

Autori: Davies Andrew J

>> Filter: Samo Article i Review

>> Sve godine

Naslov Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study (Meeting Abstract)
Autori Davies Andrew J Mihaljevic Biljana S  Mercadal Santiago Mihaylov Georgi Leppa Sirpa Cotting Denise Veenstra Klaas Zharkov Artem Dixon Mark Barrett Martin Macdonald David 
Info BLOOD, (2016), vol. 128 br. 22, str. -
Projekat Takeda Pharmaceutical Company Ltd; Mundipharma; GSKGlaxoSmithKline; Karyopharma; Roche Holding; Gilead Sciences; Bayer AG; Pfizer; JanssenJohnson & Johnson USAJanssen Biotech Inc; Mundipharma; CTI Bio Pharma
Ispravka Web of Science   Članak   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Pharmacokinetics (PK), Safety and Overall Response Rate (ORR) Achieved with Subcutaneous (SC) Administration of Rituximab in Combination with Chemotherapy Were Comparable to Those Achieved with Intravenous (IV) Administration in Patients (pts) with Follicular Lymphoma (FL) in the First-Line Setting: Stage 1 Results of the Phase III SABRINA Study (BO22334) (Meeting Abstract)
Autori Davies Andrew J Merli Francesco Mihaljevic Biljana S  Siritanaratkul Noppadol Solal-Celigny Philippe Boehnke Axel Berge Claude McIntyre Christine Barrett Martin Macdonald David 
Info BLOOD, (2012), vol. 120 br. 21, str. -
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
>> Sve godine

Ispis zapisa u formatu:TXT | BibTeX